FOR TECHNOLOGY TRANSFER OFFICES

More disclosures than budget.
Every year.

IP8 helps technology transfer offices decide which disclosures justify a filing, which patents justify continued maintenance, and which of them somebody in the market may already have a reason to license.

Which inventions deserve investment? Which patents can be licensed? Who might license them?
Triage Disclosures Assess Claimable Whitespace Rationalize Maintenance Costs Uncover Active Licensees
Annual Portfolio Triage & Licensing
Evidence-Backed
Disclosures
Stage 01
1,482 −12.4%
Initial submissions triaged
Filings
Stage 02
864 −8.7%
Defensible whitespace cleared
Licensed
Stage 03
327 Active
Commercialized agreements
58% Conversion to Filing 38% Licensing Yield
Novelty & Whitespace Screening
618 unclaimable disclosures filtered early — saves prosecution spend
+$1.2M saved
Maintenance Rationalization
Cuts renewal spend on non-earning assets; protects core moats
352 pruned
Active Licensee Mapping
Maps surviving claims to commercial products with citation backing
148 targets

A small number of early decisions
carry the whole portfolio.

Disclosures arrive faster than filings can be funded. Most patents will never produce a licence. Maintenance costs compound on assets filed optimistically years ago and never revisited. And the researcher whose disclosure you decline is a colleague you'll see in the corridor next week.

So the office is judged on a handful of early decisions, made with limited information against a budget that doesn't flex, and the two most common failures are opposite: filing on too much and running out of money for the one that mattered, or declining something because there was no time to look properly.

Compounding Maintenance Traps
Legacy patents filed optimistically accumulate costly renewal fees year after year without licensing traction, slowly starving the office of budget for new breakthroughs.
High-Impact Commercial Triage
Consistent early scoring separates true commercial potential from defensive noise, ensuring filings target claimable whitespace that attracts commercial licensees.

Three decisions,
and what informs each one.

Fewer speculative filings. Fewer maintenance fees on assets nobody will license. More conversations that start with evidence.

1
Which disclosures justify a filing?
Novelty Intelligence finds threatening prior art and shows what claim scope may still survive, helping you judge whether a disclosure is worth filing before prosecution begins.
Explore Novelty Intelligence →
2
Which patents justify continued maintenance?
Portfolio Intelligence separates assets with real strategic or commercial value from those that have quietly become a cost, with reasoning that supports each decision.
Explore Portfolio Intelligence →
3
Who might actually license this?
Monetization Intelligence finds products and companies whose technology maps to the patent claims, giving TTOs a clearer view of realistic licensing targets.
Explore Monetization Intelligence →
Fewer speculative filings. Fewer maintenance fees on assets nobody will license. More conversations that start with evidence.

Declining a disclosure is a conversation,
not an email.

Every technology transfer decision has a researcher on the other side of it, and some of them will disagree.

Constructive Researcher Conversations
Instead of saying “we didn't have the budget,” show the prior art, what it covers, and what may still be claimable. That makes the conversation clearer and more productive.
Defensible Committee & Board Reporting
Consistent portfolio assessments make it easier to justify spend and report commercialization potential with evidence rather than narrative alone.
Evidence-Backed Decisions
Evidence turns difficult cuts or rejections into transparent, professional decisions that others can understand and examine.
Evidence turns a budget decision into a professional judgment the other person can examine.

Bring the next patent decision to IP8.

Triage disclosures against global prior art, rationalize maintenance budgets, and uncover active commercial licensees with citation-backed evidence.

IP8 | The Patent Decision Intelligence Platform.

The Patent Decision Intelligence Platform. Built by the team behind PatSeer to unlock evidence-backed portfolio intelligence and patent clearance.

ISO 27001 SOC 2 Type 2
PIFC 2026
Sept 16 – Sept 18
AIPLA 2026 Annual Meeting
Oct 29 – Oct 31

Speak with our patent intelligence team or schedule a personalized walkthrough.

IP8® is a registered trademark • Copyright © 2026. All rights reserved.

The Patent Decision Intelligence Platform. Built by the team behind PatSeer to unlock evidence-backed portfolio intelligence and patent clearance.

ISO 27001 SOC 2 Type 2
PIFC 2026
Sept 16 – Sept 18
AIPLA 2026 Annual Meeting
Oct 29 – Oct 31

Speak with our patent intelligence team or schedule a personalized walkthrough.